HC Wainwright & Co. Reiterates Buy on Ascendant Resources, Maintains C$0.45 Price Target
HC Wainwright & Co. analyst Heiko Ihle reiterates Ascendant Resources (TSX:ASND) with a Buy and maintains C$0.45 price target.
Needham Reiterates Buy on Clearside Biomedical, Maintains $5 Price Target
Needham analyst Serge Belanger reiterates Clearside Biomedical (NASDAQ:CLSD) with a Buy and maintains $5 price target.
Johnson & Johnson’s Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Cantor Fitzgerald is previewing its thoughts on a potential interim analysis for Johnson & Johnson’s (NYSE:JNJ) Phase 3 MARIPOSA study of Rybrevant (amivantamab)…
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $2 price target.
‘The Year Of The Efficient Rabbit’: Why Analysts Are Raising Their Price Targets On Meta Platforms (Including One Doubling The PT)
Social media and metaverse company Meta Platforms Inc (NASDAQ: META) reported fourth quarter financial results and first quarter guidance af
HC Wainwright & Co. Reiterates Buy on DMG Blockchain Solutions, Maintains C$1 Price Target
HC Wainwright & Co. analyst Kevin Dede reiterates DMG Blockchain Solutions (TSXV:DMGI) with a Buy and maintains C$1 price target.
HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 price target.
HC Wainwright & Co. Reiterates Buy on U.S. Gold, Maintains $10.5 Price Target
HC Wainwright & Co. analyst Heiko Ihle reiterates U.S. Gold (NASDAQ:USAU) with a Buy and maintains $10.5 price target.
